<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapies that target <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and the VEGF pathway are a component of treatment for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>Bevacizumab is a humanized monoclonal antibody that binds to VEGFA </plain></SENT>
<SENT sid="2" pm="."><plain>Chemotherapy plus bevacizumab has led to improved outcomes for mCRC patients </plain></SENT>
<SENT sid="3" pm="."><plain>Despite these benefits, progressive disease invariably ensues </plain></SENT>
<SENT sid="4" pm="."><plain>Multiple members of the VEGF family can potentially contribute to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and/or evasion of antiangiogenic therapy if one pathway should be inhibited </plain></SENT>
<SENT sid="5" pm="."><plain>Aflibercept, a new biological agent, is a multiple angiogenic factor trap that prevents not only VEGFA, but also VEGFB and PlGF from activating their native receptors </plain></SENT>
<SENT sid="6" pm="."><plain>Key clinical data for bevacizumab and aflibercept for treatment of mCRC, clinical evidence for use of these agents beyond progression, and the search for angiogenic biomarkers to better define patients most likely to benefit from these interventions will be reviewed </plain></SENT>
</text></document>